Comparison · NCT05520138-deaths
Abiraterone vs Enzalutamide: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abiraterone vs Enzalutamide: deaths from any cause. Trial comparisons, record NCT05520138-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05520138-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.867 | 0.854 | 0.879 | wilson | |
| Risk in group 2 | 0.839 | 0.824 | 0.852 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0282 | 0.00944 | 0.047 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 1.01 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 1.25 | 1.08 | 1.45 | log | |
| Number needed to harm, for one more death from any cause on Abiraterone than on Enzalutamide | 35.5 | 21.3 | 106 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abiraterone | Participants with mCRPC who initiated abiraterone during the index period in real-world setting and whose data were observed in the study, were included in this reporting group. | 2,523 | 2,911 | EG000 |
| Group 2 | Enzalutamide | Participants with mCRPC who initiated enzalutamide during the index period in real-world setting and whose data were observed in the study, were included in this reporting group. | 2,176 | 2,595 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT number
- NCT05520138
- Phases
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Enzalutamide, Abiraterone acetate
- Lead sponsor
- Pfizer
- Results first posted
- 2024-09-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05520138?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05520138-deaths